MX365658B - Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. - Google Patents

Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.

Info

Publication number
MX365658B
MX365658B MX2016014813A MX2016014813A MX365658B MX 365658 B MX365658 B MX 365658B MX 2016014813 A MX2016014813 A MX 2016014813A MX 2016014813 A MX2016014813 A MX 2016014813A MX 365658 B MX365658 B MX 365658B
Authority
MX
Mexico
Prior art keywords
orf
antibody constructs
aav
expression
compositions
Prior art date
Application number
MX2016014813A
Other languages
English (en)
Other versions
MX2016014813A (es
Inventor
James M Wilson
Tretiakova Anna
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2016014813A publication Critical patent/MX2016014813A/es
Publication of MX365658B publication Critical patent/MX365658B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C12N2830/205—Vector systems having a special element relevant for transcription transcription of more than one cistron bidirectional
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)

Abstract

La presente invención se refiere a un virus adenoasociado (AAV) recombinante caracterizado porque tiene una cápside de AAV y empaquetado en ella un ácidonucleico heterólogo que expresa al menos dos anticuerpos funcionales monoespecíficos en una célula, en donde el AAV recombinante comprende: una repetición terminal invertida (ITR) 5´de AAB; un primer inmunoglobulina bajo el control de secuencias de control reguladoras que dirigen su expresión que codifica al de secuencias de control reguladoras que dirigen su expresión; un segundo casete de expresión que comprende un segundo ORF, un conector, y un tercer ORF bajo el control de secuencias de control reguladoras que dirigen su expresión, en donde el segundo y el tercer ORF son para un segundo y un tercer constructo de inmunoglobulina; y una ITR 3´de AAV.
MX2016014813A 2014-05-13 2015-05-13 Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos. MX365658B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461992649P 2014-05-13 2014-05-13
PCT/US2015/030533 WO2015175639A1 (en) 2014-05-13 2015-05-13 Compositions comprising aav expressing dual antibody constructs and uses thereof

Publications (2)

Publication Number Publication Date
MX2016014813A MX2016014813A (es) 2017-03-10
MX365658B true MX365658B (es) 2019-06-10

Family

ID=54480597

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014813A MX365658B (es) 2014-05-13 2015-05-13 Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos.

Country Status (27)

Country Link
US (4) US10138295B2 (es)
EP (1) EP3142750B1 (es)
JP (3) JP6974943B2 (es)
KR (1) KR102550926B1 (es)
CN (1) CN106470736B (es)
AU (2) AU2015259188B2 (es)
CA (1) CA2947614C (es)
CL (1) CL2016002840A1 (es)
CR (1) CR20160519A (es)
DK (1) DK3142750T3 (es)
EA (1) EA037980B1 (es)
ES (1) ES2833230T3 (es)
HR (1) HRP20201530T1 (es)
HU (1) HUE050609T2 (es)
IL (1) IL248508B2 (es)
MA (2) MA44179B1 (es)
MX (1) MX365658B (es)
MY (1) MY186389A (es)
PE (1) PE20170261A1 (es)
PH (1) PH12016502239B1 (es)
PL (1) PL3142750T3 (es)
PT (1) PT3142750T (es)
SA (1) SA516380285B1 (es)
SG (1) SG11201609207SA (es)
SI (1) SI3142750T1 (es)
UA (1) UA123986C2 (es)
WO (1) WO2015175639A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos
AU2016275909A1 (en) 2015-05-13 2017-11-09 The Trustees Of The University Of Pennsylvania AAV-mediated expression of anti-influenza antibodies and methods of use thereof
US11174495B2 (en) 2015-12-04 2021-11-16 Board Of Regents, The University Of Texas System Reporter system for detecting and targeting activated cells
KR20240005973A (ko) * 2016-04-15 2024-01-12 리젠엑스바이오 인크. 완전히-인간형의 번역후 변형된 항-VEGF Fab를 이용한 눈 질환의 치료
AU2017248731A1 (en) * 2016-04-15 2018-10-18 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
WO2017184463A1 (en) * 2016-04-17 2017-10-26 The Trustees Of The University Of Pennsylvania Compositions and methods useful for prophylaxis of organophosphates
WO2017189959A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189964A2 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
AU2017264562B2 (en) 2016-05-12 2023-03-09 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
MX2018015540A (es) * 2016-06-20 2019-04-11 Janssen Vaccines & Prevention Bv Promotor bidireccional potente y equilibrado.
JP2020510430A (ja) 2017-02-28 2020-04-09 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Ａａｖベクターに基づくインフルエンザワクチン
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
SI3589730T1 (sl) 2017-02-28 2024-04-30 The Trustees Of The University Of Pennsylvania Adeno-povezan virus (AAV) clade F vektor in njihova uporaba
CN111246854A (zh) * 2017-08-17 2020-06-05 宾夕法尼亚大学理事会 编码单纯疱疹病毒糖蛋白的修饰mrna疫苗及其用途
EP3727468A4 (en) 2017-12-19 2021-09-22 Akouos, Inc. AAV-MEDIATED DELIVERY OF THERAPEUTIC ANTIBODIES TO THE INNER EAR
CN108424934A (zh) * 2018-04-16 2018-08-21 和元生物技术（上海）股份有限公司 一种慢病毒cag-cmv双启动子改造载体构建及应用
SG11202101157VA (en) * 2018-08-09 2021-03-30 Bioverativ Therapeutics Inc Nucleic acid molecules and uses thereof for non-viral gene therapy
US20200148762A1 (en) * 2018-11-09 2020-05-14 Avamab Pharma Inc. Methods for regulating endogenous production of antibodies against infectious diseases
EP3898965A4 (en) * 2018-12-21 2022-10-12 Merck Sharp & Dohme Corp. EXPRESSION VECTORS FOR EUKARYOT EXPRESSION SYSTEMS
KR20210130158A (ko) 2019-01-31 2021-10-29 오레곤 헬스 앤드 사이언스 유니버시티 Aav 캡시드의 전사 의존적 유도 진화를 사용하는 방법
EP4247857A1 (en) * 2020-11-23 2023-09-27 Novartis AG Expression technology for antibody constructs
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
CA3207224A1 (en) * 2021-02-02 2022-08-11 Bryan GORE Artificial expression constructs for modulating gene expression in gabaergic neurons and astrocytes
CN116751284B (zh) * 2023-06-13 2024-06-04 康元医疗科技(大连)有限公司 一种纳米抗体、包含该纳米抗体的多肽及其应用

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US5811524A (en) 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
AU728220B2 (en) 1997-04-14 2001-01-04 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant AAV product
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US5891994A (en) 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
GB9720585D0 (en) 1997-09-26 1997-11-26 Smithkline Beecham Biolog Vaccine
CZ121599A3 (cs) * 1998-04-09 1999-10-13 Aventis Pharma Deutschland Gmbh Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
JP2002538770A (ja) 1998-11-10 2002-11-19 ユニバーシティ オブ ノース カロライナ アット チャペル ヒル ウイルスベクターとその製造及び投与の方法
DK1204739T3 (da) 1999-08-09 2008-10-20 Targeted Genetics Corp Forögelse af ekspression af en enkeltstrenget, heterolog nukleotidsekvens fra rekombinante, virale vektorer ved en sådan udformning af sekvensen at den danner intrastrengbasepar
US6780639B1 (en) * 1999-08-24 2004-08-24 Universite Libre De Bruxelles Antibiotic inducible/repressible genetic construct for gene therapy or gene immunization
HUP0204250A3 (en) 2000-01-31 2005-06-28 Smithkline Beecham Biolog Use of hiv-protein or -polynucleotide for vaccine produce
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
AU2001269723B9 (en) 2000-06-01 2006-11-16 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
EP2338900B1 (en) 2001-11-13 2014-01-01 The Trustees of The University of Pennsylvania Adeno-associated virus (AAV) Cy.5 sequences, vectors containing the same and uses thereof
CA2469785C (en) 2001-12-17 2014-04-22 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
CA2965865C (en) * 2002-07-18 2021-10-19 Merus N.V. Recombinant production of mixtures of antibodies
ATE431423T1 (de) 2003-01-21 2009-05-15 Chugai Pharmaceutical Co Ltd Verfahren zum screening der leichten kette eines antikörpers
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
US20080050357A1 (en) 2003-08-01 2008-02-28 Claes Gustafsson Systems and Methods for Antibody Engineering
CN102199626B (zh) 2003-09-30 2015-06-24 宾夕法尼亚大学托管会 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用
US20060246079A1 (en) 2003-11-14 2006-11-02 Morrow Phillip R Neutralizing human antibodies to anthrax toxin
WO2005108568A1 (en) 2004-05-10 2005-11-17 Basf Plant Science Gmbh Methods for assembling multiple expression constructs
EP1765846A4 (en) 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
CN101203613B (zh) 2005-04-07 2012-12-12 宾夕法尼亚大学托管会 增强腺相关病毒载体功能的方法
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
US20070292922A1 (en) 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
WO2007127264A2 (en) 2006-04-28 2007-11-08 The Trustees Of The University Of Pennsylvania Scalable production method for aav
BRPI0807952A2 (pt) 2007-02-20 2014-06-10 Anaptysbio Inc Sistemas de hipermutação somática
WO2008124934A1 (en) 2007-04-17 2008-10-23 National Research Council Of Canada Constructs for enhancement of gene expression in muscle
US7879326B2 (en) 2007-06-15 2011-02-01 The Board Of Trustees Of The Leland Stanford Junior University Human neutralizing monoclonal antibodies to H5N1 influenza A virus
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
BRPI0911699B8 (pt) 2008-07-25 2023-02-28 Inst Res Biomedicine vetor, célula, composição farmacêutica, uso de um anticorpo, ou fragmento de ligação a antígeno deste
JP2012515540A (ja) * 2009-01-26 2012-07-12 ゲンマブ エー／エス 抗体混合物を産生するための方法
JP5757534B2 (ja) 2009-03-25 2015-07-29 ジェネンテック， インコーポレイテッド 抗ｆｇｆｒ３抗体およびこれを用いた方法
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN102448986B (zh) 2009-05-11 2015-11-25 克鲁塞尔荷兰公司 能中和流感病毒h3n2的人结合分子及其应用
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
RU2560420C2 (ru) * 2009-06-25 2015-08-20 МЕДИММЬЮН, ЭлЭлСи Варианты гемагглютининов вируса свиного гриппа
CN101649328A (zh) * 2009-09-09 2010-02-17 陕西师范大学 表达多个外源基因的Ad5 D24条件复制型腺病毒载体及其构建方法和应用
US8598331B2 (en) 2009-09-28 2013-12-03 The University Of British Columbia CLDN5 mini-promoters
HUE026229T2 (en) 2010-02-08 2016-06-28 Regeneron Pharma Common light chain mouse
CN102933949A (zh) 2010-03-30 2013-02-13 巴特尔纪念研究所 血沉棕黄层分离浮子系统及方法
KR20130065665A (ko) 2010-05-11 2013-06-19 아베오 파마슈티컬즈, 인크. 항-fgfr2 항체
CN103347894B (zh) 2010-06-19 2017-05-10 纪念斯隆-凯特林癌症中心 抗gd2抗体
EP2603530B1 (en) 2010-08-13 2017-11-08 Roche Glycart AG Anti-fap antibodies and methods of use
CA2808482C (en) * 2010-08-16 2021-10-26 Novimmune S.A. Methods for the generation of multispecific and multivalent antibodies
JP6091435B2 (ja) * 2011-02-22 2017-03-08 カリフォルニア インスティチュート オブ テクノロジー アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery
SG185832A1 (en) 2011-05-10 2012-12-28 Agency Science Tech & Res Fgfr1 antibodies and treatment of cancer
KR20140021589A (ko) 2011-04-07 2014-02-20 제넨테크, 인크. 항-fgfr4 항체 및 사용 방법
EP2699688A1 (en) 2011-04-20 2014-02-26 The Trustees Of The University Of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
WO2012145759A2 (en) 2011-04-21 2012-10-26 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Methods of protein production and compositions thereof
CN103842601A (zh) 2011-09-29 2014-06-04 艾利丹尼森公司 增加营销机会的防盗安全装置
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013059206A2 (en) 2011-10-17 2013-04-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-growth factor ii (igf-ii)
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013155222A2 (en) 2012-04-10 2013-10-17 The Regents Of The University Of California Brain-specific enhancers for cell-based therapy
WO2013163427A1 (en) * 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Antibodies to treat hiv-1 infection
EP2852615B1 (en) 2012-05-22 2018-12-05 Bristol-Myers Squibb Company Il-17a/f il-23 bispecific antibodies and their uses
RS60318B1 (sr) * 2012-08-01 2020-07-31 Ikaika Therapeutics Llc Ublažavanje tkivnog oštećenja i fibroze pomoću anti-ltbp4 antitela
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
PE20170261A1 (es) 2014-05-13 2017-04-12 Univ Pennsylvania Composiciones que comprenden virus adenoasociado (aav) que expresa constructos de anticuerpos duales y sus usos

Also Published As

Publication number Publication date
PL3142750T3 (pl) 2021-03-08
CR20160519A (es) 2017-01-27
MY186389A (en) 2021-07-22
SI3142750T1 (sl) 2020-11-30
UA123986C2 (uk) 2021-07-07
JP6974943B2 (ja) 2021-12-01
EP3142750B1 (en) 2020-07-01
IL248508B (en) 2022-10-01
SG11201609207SA (en) 2016-12-29
US20190031740A1 (en) 2019-01-31
JP7229298B2 (ja) 2023-02-27
EP3142750A1 (en) 2017-03-22
PE20170261A1 (es) 2017-04-12
PH12016502239A1 (en) 2017-01-09
SA516380285B1 (ar) 2020-04-30
AU2015259188A1 (en) 2016-11-10
CA2947614C (en) 2023-10-03
MA44179B1 (fr) 2020-10-28
MA44179A1 (fr) 2019-07-31
BR112016026092A2 (pt) 2017-12-12
JP2017515482A (ja) 2017-06-15
US20200216520A1 (en) 2020-07-09
PH12016502239B1 (en) 2017-01-09
AU2021204630B2 (en) 2024-03-14
CL2016002840A1 (es) 2017-05-05
JP2020141697A (ja) 2020-09-10
HUE050609T2 (hu) 2021-01-28
AU2015259188B2 (en) 2021-07-29
US10647758B2 (en) 2020-05-12
US10385119B2 (en) 2019-08-20
MX2016014813A (es) 2017-03-10
KR20170002445A (ko) 2017-01-06
CA2947614A1 (en) 2015-11-19
IL248508B2 (en) 2023-02-01
US10138295B2 (en) 2018-11-27
NZ725622A (en) 2023-10-27
US20170081392A1 (en) 2017-03-23
MA39437A1 (fr) 2018-01-31
HRP20201530T1 (hr) 2020-12-11
EP3142750A4 (en) 2017-10-18
CN106470736B (zh) 2021-05-28
AU2021204630A1 (en) 2021-07-29
EA037980B1 (ru) 2021-06-18
KR102550926B1 (ko) 2023-07-05
DK3142750T3 (da) 2020-09-14
EA201692293A1 (ru) 2017-04-28
JP2021121217A (ja) 2021-08-26
ES2833230T3 (es) 2021-06-14
WO2015175639A1 (en) 2015-11-19
CN106470736A (zh) 2017-03-01
US10975140B2 (en) 2021-04-13
US20190322725A1 (en) 2019-10-24
IL248508A0 (en) 2016-12-29
PT3142750T (pt) 2020-09-22

Similar Documents

Publication Publication Date Title
PH12016502239A1 (en) Compositions comprising aav expressing dual antibody constructs and uses thereof
ECSP20024555A (es) Anticuerpos especificos para cd47 y pd-l1
CY1120951T1 (el) Ανθρωπινα αντισωματα enanti-tau
CL2017001866A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
EP4275698A3 (en) Anti-tigit antibodies and methods of use thereof
EA201792184A1 (ru) Антитела, направленные против т-клеточного иммуноглобулина и белка муцина 3 (tim-3)
JP2017515482A5 (es)
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
BR112015026823A2 (pt) Polipeptídeo de cadeia pesada de imunoglobulina isolada, polipeptídeo de cadeia leve de imunoglobulina isolada, sequência de ácido nucleico isolada ou purificada, vetor, agente de ligação de proteína de morte-1 programada (pd-1) isolada, célula isolada, composição, e uso do agente de ligação da pd-1 isolada
WO2014025546A3 (en) Anti-dengue virus antibodies and uses thereof
EA201491186A1 (ru) Полипептиды химерного фактора viii и их применение
NI201800113A (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
WO2017124001A3 (en) T cell receptor-like antibodies specific for foxp3-derived peptides
WO2018194496A3 (ru) Моноклональное антитело к pd-l1
CR20210094A (es) ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193)
ZA202201464B (en) Anti-tigit antibodies and application thereof
WO2018069947A8 (en) Nucleotide sequence expressing an exosome-anchoring protein for use as vaccine
AR126090A2 (es) Anticuerpo o fragmento de unión al antígeno de este, molécula de adn, vector de clonación o expresión y célula hospedadora
CY1120686T1 (el) Αντισωματα ειδικα για το ανθρωπινο πολυπεπτιδιο αμυλοειδους των νησιδιων (ηιαρρ) και χρησεις αυτων

Legal Events

Date Code Title Description
FG Grant or registration